Searchable abstracts of presentations at key conferences in endocrinology

ea0013p306 | Thyroid | SFEBES2007

Outcome of radio-active iodine treatment for thyrotoxicosis in Glan Clwyd Hospital 2003–2005

Swidan Ahmed , Platts Julia , Hassanein Mohammed

Background: There is controversy about the ideal outcome for radio-active iodine (RAI) treatment in thyrotoxicosis and the optimal dose to be given. Various centres use various doses ranging from 185 mBq to 550 mBq.Aim: Our aim was to determine the thyroid status post RAI treatment for thyrotoxicosis and in those who became hypothyroid, to assess the time of onset of hypothyroidism from the date of RAI treatment administration.Meth...

ea0011oc28 | Diabetes and metabolism | ECE2006

11β-Hydroxysteroid dehydrogenase type 1 oxo-reductase activity is increased in patients with alcoholic chronic liver disease: the key to the phenotype of the alcoholic pseudo-Cushing’s state?

Ahmed A , Saksena S , Elias E , Stewart PM

The pseudo-Cushing’s syndrome that accompanies both acute alcohol ingestion and alcohol withdrawal is an important differential diagnosis of hypercortisolism that is poorly understood. Two isozymes of 11β-hydroxysteroid dehydrogenase (11β-HSD) interconvert hormonally active cortisol (F) and inactive cortisone (E). Previously we have shown higher urinary F:E metabolite ratios (a reflection of total body 11βHSD activity) in patients with alcoholic liver disea...

ea0011p19 | Bone | ECE2006

The effect of ceramide on IGF-1 induced proliferation in growth plate chondrocytes

MacRae VE , Ahmed SF , Farquharson C

Abnormal growth patterns are commonly observed in children suffering from chronic inflammatory diseases. These disorders are associated with the increased production of pro-inflammatory cytokines, which inhibit growth plate chondrocyte dynamics. Ceramide, a sphingosine-based lipid second messenger, mediates many of the actions of pro-inflammatory cytokines. Ceramide inhibits IGF-1 signalling and induces apoptosis in numerous cell types. This study determined the effects of C2-...

ea0008p9 | Clinical case reports | SFE2004

Conservative management of a visual field defect

Ahmed TJ , Simpson-Davis S , Seal L

Mrs. P.A., a 75 year old lady, presented to Accident and Emergency with a severe persistent headache of 3 days duration. She was disorientated and drowsy. She has a history of type 2 diabetes, hypertension, hypercholesterolaemia, depression and hypothyroidism. She was a smoker of 20 a day and consumed no alcohol. Her Glasgow Coma Scale was 13/15, her examination was normal. An initial CT head showed a pituitary tumour with haemorrhage. Tests showed an FSH of 14.1 IU/L, LH 2.9 ...

ea0007p139 | Growth and development | BES2004

Transdermal testosterone application: pharmacokinetics and effects on pubertal status, short-term growth and bone turnover

Ahmed S , Mayo A , Macintyre H , Wallace A

Aim - To assess the effect of transdermal testosterone (TT) on free testosterone concentrations in saliva and on short-term growth and bone turnover in boys with growth or pubertal delay.Method - Prospective, randomized, cross-over study over 26 weeks with 4 weeks of Run-In, 8 weeks of Treatment I (8 hours/12 hours), 4 weeks of Wash-Out, 8 weeks of Treatment II (8 hours/12 hours) and 4 weeks of final Wash-Out.Main Outcome Measures ...

ea0006oc23 | Neuroendocrinology | SFE2003

Receptor Shedding: A Novel Mechanism for the Disinhibition of CNS Neuronal Growth

Ahmed Z , Dent R , Berry M , Logan A

The promiscuous low affinity neurotrophin co-receptor p75NTR, a member of the nerve tumor necrosis factor (TNF) receptor superfamily, mediates neuronal survival as well as death, and interacts with Trk receptors to increase their affinity for neurotrophins. Furthermore, p75NTR is the transmembrane signalling moiety which associates with the NOGO binding receptor for all CNC myelin-derived axon growth inhibitors in the injured CNS. We have shown in rats that intravitreal implan...

ea0056p55 | Adrenal cortex (to include Cushing's) | ECE2018

Abnormal salivary cortisol result in patient with low probability of Cushing disease

Ahmed Ali , Shah Najeeb , Mohammed Kamrudeen

We presenting a case of 26 old lady who is known to have Denys-Drash syndrome, epilepsy and bronchial asthma who presented with history of recent significant weight gain, extensive abdominal bruising and significant muscle weakness which she described literally as not able to use her upper limbs to move to help shuffle her bottom in the floor, a manoeuvre that she was able to do before. Patient is on Carbamazepine, sodium valporate, levetiracetam , salbutamol and Pulmicort inh...

ea0056p332 | Diabetes (to include epidemiology, pathophysiology) | ECE2018

Estimation of HbA1c in hospitalized patients with bronchial asthma

Qasim Bayar , Haj Safer , Ahmed Herish

Background: Asthma is a chronic inflammatory respiratory disease. Stress hormones may increase in asthma and expected to induce hyperglycemia. Some anti-asthma medications increase blood glucose levels e.g. Beta-agonist, while others are known hyperglycemic agent’s e.g. steroids. People who have experienced stress hyperglycemia during severe illness have a threefold risk of developing diabetes in subsequent years, and it may be appropriate to screen for diabetes in surviv...

ea0002p38 | Endocrine tumours and neoplasia | SFE2001

Effect of metallopeptidase inhibitors and growth factors on MCF-7 cell proliferation

Ahmed M , Schrey M , Parish D

Regulatory peptides are known to have a role in tumour growth. Local peptide concentrations will be affected by their proteolytic release from precursors, together with the rate of their proteolytic degradation. In this study three inhibitors of proteolysis were examined, Captopril, an ACE inhibitor, Thiorphan an inhibitor of Neutral Endopeptidase and Phosphoramidon which inhibits both Neutral Endopeptidase and also Endothelin Converting Enzyme (ECE). The effect of these inhib...

ea0073aep118 | Calcium and Bone | ECE2021

A retrospective review of the management of skeletal effects following thyroid stimulating hormone suppression therapy (tshst) in patients treated for differentiated thyroid carcinoma (dtc)

Beeharry Deepa , Ahmed Simra , Sharma Dushyant

BackgroundThyrotropin Stimulating Hormone Suppression Therapy (TSHST) in Differentiated Thyroid cancer (DTC) patients can result in reduced bone mineral density (BMD) which is a potential serious problem [1]. Studies on the effects of TSHST on BMD have demonstrated conflicting results [2–5]. There is insufficient guidance regarding the degree and duration of TSHST in the context of skeletal effects despite multiple existing guidelines.<p class="...